Skip to content 
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California. more
| Time Frame | AEON | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 26.45% | 0.81% | 0.49% |
| 1-Month Return | - | 1.2% | 1.02% |
| 3-Month Return | 27.66% | 3.24% | 3.34% |
| 6-Month Return | 64.16% | 14.99% | 7.04% |
| 1-Year Return | -85.51% | 7.42% | 11.68% |
| 3-Year Return | -99.84% | 20.71% | 71.63% |
| 5-Year Return | -99.83% | 37.45% | 75.56% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 2.52M | - | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | 2.52M | - | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | 100.00% | - | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 18.91M | 65.85M | 48.43M | 348.09M | (72.98M) | [{"date":"2020-12-31","value":5.43,"profit":true},{"date":"2021-12-31","value":18.92,"profit":true},{"date":"2022-12-31","value":13.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-20.97,"profit":false}] |
| Operating Income | (16.39M) | (65.85M) | (48.43M) | (348.09M) | 72.98M | [{"date":"2020-12-31","value":-22.45,"profit":false},{"date":"2021-12-31","value":-90.22,"profit":false},{"date":"2022-12-31","value":-66.35,"profit":false},{"date":"2023-12-31","value":-476.93,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (16.54M) | - | - | - | - | [{"date":"2020-12-31","value":-1654000000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Pre-Tax Income | (32.91M) | (55.64M) | (52.56M) | (384.63M) | 42.01M | [{"date":"2020-12-31","value":-78.35,"profit":false},{"date":"2021-12-31","value":-132.45,"profit":false},{"date":"2022-12-31","value":-125.12,"profit":false},{"date":"2023-12-31","value":-915.68,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income Taxes | 15.00K | 28.97M | (160.49K) | - | - | [{"date":"2020-12-31","value":0.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.55,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | (32.93M) | - | - | - | - | [{"date":"2020-12-31","value":-3292800000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (32.91M) | (55.64M) | (52.56M) | - | 42.01M | [{"date":"2020-12-31","value":-78.35,"profit":false},{"date":"2021-12-31","value":-132.45,"profit":false},{"date":"2022-12-31","value":-125.12,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (32.91M) | (55.64M) | (52.56M) | (384.63M) | 42.01M | [{"date":"2020-12-31","value":-78.35,"profit":false},{"date":"2021-12-31","value":-132.45,"profit":false},{"date":"2022-12-31","value":-125.12,"profit":false},{"date":"2023-12-31","value":-915.68,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| EPS (Diluted) | - | (9.54) | 13.31 | (32.84) | (2.99) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-71.73,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-246.85,"profit":false},{"date":"2024-12-31","value":-22.51,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| AEON | |
|---|---|
| Cash Ratio | 0.72 |
| Current Ratio | 0.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AEON | |
|---|---|
| ROA (LTM) | -129.01% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AEON | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 3.28 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.28 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AEON | |
|---|---|
| Trailing PE | NM |
| Forward PE | 1.16 |
| P/S (TTM) | 97.16 |
| P/B | 0.00 |
| Price/FCF | NM |
| EV/R | 201.68 |
| EV/Ebitda | NM |
AEON Biopharma, Inc. (AEON) share price today is $1.151
Yes, Indians can buy shares of AEON Biopharma, Inc. (AEON) on Vested. To buy
Yes, you can purchase fractional shares of AEON Biopharma, Inc. (AEON) via the Vested app. You can start investing in AEON Biopharma, Inc. (AEON) with a minimum investment of $1.
You can invest in shares of AEON Biopharma, Inc. (AEON) via Vested in three simple steps:
The 52-week high price of AEON Biopharma, Inc. (AEON) is $9.71. The 52-week low price of AEON Biopharma, Inc. (AEON) is $0.38.
The price-to-earnings (P/E) ratio of AEON Biopharma, Inc. (AEON) is
The price-to-book (P/B) ratio of AEON Biopharma, Inc. (AEON) is 0.00
The dividend yield of AEON Biopharma, Inc. (AEON) is 0.00%
The market capitalization of AEON Biopharma, Inc. (AEON) is $30.36M
The stock symbol (or ticker) of AEON Biopharma, Inc. is AEON
Consider the share price of AEON Biopharma, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether AEON Biopharma, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in AEON Biopharma, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the AEON Biopharma, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of AEON Biopharma, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that AEON Biopharma, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
